We are live on ! Find out more
ICM

Invenomic Capital Management Portfolio holdings

AUM $2.18B
1-Year Est. Return 0.03%
This Fund
S&P 500
This Quarter Est. Return
-4.09%
1 Year Est. Return
+0.03%
3 Year Est. Return
-6.37%
5 Year Est. Return
-25.27%
10 Year Est. Return
AUM
$468M
AUM Growth
+$160M
Cap. Flow
+$174M
Cap. Flow %
37.12%
Top 10 Hldgs %
25.86%
Holding
170
New
51
Increased
61
Reduced
22
Closed
28

Top Sells

Rank Stock Value
1
DLTR icon
Dollar Tree
DLTR
+$5M
2
CIVI
Civitas Resources
CIVI
+$4.58M
3
BABA icon
Alibaba
BABA
+$4.31M
4
CNC icon
Centene
CNC
+$4.16M
5
PRU icon
Prudential Financial
PRU
+$3.94M

Sector Composition

Rank Sector Weight
1 Technology 14.78%
2 Consumer Discretionary 12.04%
3 Healthcare 11.59%
4 Financials 10.04%
5 Materials 9.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$445B
$25.1M 5.37%
+63,100
New +$24.4M
LRN icon
2
Stride
LRN
$4.08B
$12.6M 2.69%
377,225
+128,022
+51% +$4.42M
HRB icon
3
H&R Block
HRB
$5.7B
$11.9M 2.54%
503,869
+111,936
+29% +$2.72M
T icon
4
AT&T
T
$169B
$11.6M 2.49%
+626,014
New +$11.7M
BPOP icon
5
Popular Inc
BPOP
$11.1B
$10.9M 2.33%
132,996
+41,856
+46% +$3.4M
RGA icon
6
Reinsurance Group of America
RGA
$15.9B
$10.1M 2.15%
91,911
+22,431
+32% +$2.49M
SPY icon
7
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$9.83M 2.1%
+20,700
New +$9.5M
CAH icon
8
Cardinal Health
CAH
$54.5B
$9.76M 2.09%
189,589
+67,590
+55% +$3.32M
IMMR icon
9
Immersion
IMMR
$254M
$9.7M 2.07%
1,698,555
+754,286
+80% +$4.96M
KGC icon
10
Kinross Gold
KGC
$28.1B
$9.54M 2.04%
1,641,537
+470,655
+40% +$2.81M
CI icon
11
Cigna
CI
$79.6B
$9.44M 2.02%
41,108
+28,010
+214% +$5.95M
JACK icon
12
Jack in the Box
JACK
$308M
$9.44M 2.02%
+107,883
New +$10M
CVSA
13
Covista Inc
CVSA
$4.3B
$8.8M 1.88%
+297,754
New +$9.81M
GTS
14
DELISTED
Triple-S Management Corporation
GTS
$8.68M 1.85%
243,208
WKC icon
15
World Kinect Corp
WKC
$2.06B
$8.14M 1.74%
307,375
+134,741
+78% +$3.84M
MCK icon
16
McKesson
MCK
$104B
$7.88M 1.68%
31,705
+10,637
+50% +$2.34M
SANM icon
17
Sanmina
SANM
$9.24B
$7.41M 1.58%
178,645
+146,468
+455% +$5.76M
TBI
18
Trueblue
TBI
$235M
$6.94M 1.48%
250,941
+72,038
+40% +$2.04M
OVV icon
19
Ovintiv
OVV
$16.4B
$6.54M 1.4%
194,041
+98,387
+103% +$3.51M
FE icon
20
FirstEnergy
FE
$28.7B
$6.16M 1.32%
148,007
+67,593
+84% +$2.61M
CBT icon
21
Cabot Corp
CBT
$4.7B
$6.01M 1.29%
107,024
+35,087
+49% +$1.93M
FBP icon
22
First Bancorp
FBP
$4.47B
$6.01M 1.28%
436,239
+347
+0.1% +$4.77K
KOP icon
23
Koppers
KOP
$965M
$5.88M 1.26%
187,735
-73,567
-28% -$2.4M
CLS icon
24
Celestica
CLS
$40.3B
$5.73M 1.23%
515,068
-21,327
-4% -$221K
INGN icon
25
Inogen
INGN
$174M
$5.62M 1.2%
+165,426
New +$6.01M

Similar funds

Invenomic Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Invenomic Capital Management held 170 positions worth $468M, up 52% from $308M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Invenomic Capital Management deployed $174M of net new capital in Q4 2021, opening 51 new positions and adding to 61 existing holdings. Its largest new stake was AT&T: 626,014 shares worth $11.6M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 7.4% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Civitas Resources, an estimated $4.58M trimmed.

  • Invenomic Capital Management's largest Q4 2021 buy was AT&T: 626,014 shares worth $11.6M.
  • Invenomic Capital Management added most to Cigna in Q4 2021, an estimated $5.95M increase.
  • Invenomic Capital Management's biggest Q4 2021 reduction was Civitas Resources, cutting an estimated $4.58M.
  • Invenomic Capital Management fully exited Dollar Tree in Q4 2021, selling an estimated $5M.
  • Invenomic Capital Management's ten largest holdings make up 26% of its $468M portfolio in Q4 2021.
  • Invenomic Capital Management opened 51 new positions and closed 28 in Q4 2021.
  • Invenomic Capital Management's portfolio value rose 52% quarter-over-quarter to $468M.

Based on Invenomic Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.